For the estimated one in ten hypertensive adults whose elevated blood pressure stems from excess aldosterone secretion, pregnancy carries risks that have been largely invisible in clinical guidelines — until now. Primary aldosteronism (PA), the most prevalent form of secondary hypertension, has historically been underdiagnosed in women of reproductive age, leaving a critical knowledge gap about how this hormonal disorder intersects with pregnancy outcomes.
In a multicenter European survey spanning 2000 to 2022, researchers tracked 102 women aged 18–45 at PA diagnosis through their first eligible pregnancy. The complication burden was substantial: 56% of pregnancies were affected by at least one adverse outcome. Preeclampsia occurred in 36% of cases, preterm birth and low birth weight each in 30%, and neonatal intensive care unit admission in 22%. Hypokalemia — a hallmark of severe PA — complicated 31% of pregnancies. The timing of diagnosis proved decisive: pregnancies that occurred before PA was identified carried significantly higher rates of maternal, fetal, and neonatal complications compared with those managed after diagnosis was established. Five independent predictors of complications emerged from multivariate analysis: uncontrolled blood pressure (OR 7.05), undiagnosed PA status (OR 4.37), North/Black African ethnicity (OR 3.69), higher BMI (OR 1.09), and greater baseline antihypertensive drug burden (OR 2.18).
This dataset fills a meaningful void, though its retrospective, survey-based design introduces recall and selection bias, and the cohort size of 102 limits statistical power for subgroup analyses. The finding that undiagnosed PA carries an odds ratio above four for complications reinforces a growing clinical argument for earlier aldosterone screening in young hypertensive women, particularly before or during pregnancy planning. The dramatic elevation in preeclampsia rates — nearly four times the general population baseline of roughly 8–10% — suggests mineralocorticoid excess may directly potentiate placental dysfunction. This is an incremental but clinically important contribution: it strengthens the case for PA as an under-recognized obstetric risk factor warranting heightened diagnostic vigilance.